NASDAQ:AXGN - AxoGen Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$20.65 +0.46 (+2.28 %)
(As of 04/23/2019 04:00 PM ET)
Previous Close$20.19
Today's Range$19.7220 - $20.9850
52-Week Range$14.13 - $56.85
Volume223,217 shs
Average Volume673,434 shs
Market Capitalization$804.21 million
P/E RatioN/A
Dividend YieldN/A
Beta0.17
AxoGen, Inc. develops and markets surgical solutions for peripheral nerve injuries. The company's surgical solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. Its solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that can be used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed. In addition, the company offers AcroVal neurosensory and motor testing system, which consists of AcroGrip for use in hand grip strength measurement; AcroPinch for measuring pinch strength; and Pressure-Specified Sensory Device, a somatosensory evaluation and measurement device. Further, it provides AxoTouch two point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals in the United States, Canada, the United Kingdom and other European countries, and internationally. AxoGen, Inc. is headquartered in Alachua, Florida.

Receive AXGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AXGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AXGN
CUSIPN/A
Phone386-462-6800

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$83.94 million
Book Value$3.84 per share

Profitability

Net Income$-22,400,000.00

Miscellaneous

EmployeesN/A
Market Cap$804.21 million
Next Earnings Date5/8/2019 (Confirmed)
OptionableOptionable

AxoGen (NASDAQ:AXGN) Frequently Asked Questions

What is AxoGen's stock symbol?

AxoGen trades on the NASDAQ under the ticker symbol "AXGN."

How were AxoGen's earnings last quarter?

AxoGen, Inc (NASDAQ:AXGN) posted its earnings results on Tuesday, February, 26th. The medical equipment provider reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.02. The medical equipment provider earned $23.40 million during the quarter, compared to the consensus estimate of $23.40 million. AxoGen had a negative return on equity of 15.77% and a negative net margin of 26.68%. The firm's revenue for the quarter was up 37.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.07) EPS. View AxoGen's Earnings History.

When is AxoGen's next earnings date?

AxoGen is scheduled to release their next quarterly earnings announcement on Wednesday, May 8th 2019. View Earnings Estimates for AxoGen.

What guidance has AxoGen issued on next quarter's earnings?

AxoGen updated its FY 2019 earnings guidance on Tuesday, February, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $109-114 million, compared to the consensus revenue estimate of $113.63 million.

What price target have analysts set for AXGN?

4 equities research analysts have issued 12-month target prices for AxoGen's shares. Their forecasts range from $26.00 to $55.00. On average, they anticipate AxoGen's stock price to reach $38.00 in the next twelve months. This suggests a possible upside of 84.0% from the stock's current price. View Analyst Price Targets for AxoGen.

What is the consensus analysts' recommendation for AxoGen?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AxoGen in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AxoGen.

Has AxoGen been receiving favorable news coverage?

Media stories about AXGN stock have been trending positive on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AxoGen earned a coverage optimism score of 2.7 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days.

Who are some of AxoGen's key competitors?

What other stocks do shareholders of AxoGen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AxoGen investors own include Intelsat (I), Xilinx (XLNX), Exelixis (EXEL), Micron Technology (MU), Bank of America (BAC), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Cypress Semiconductor (CY), Fossil Group (FOSL) and AMC Entertainment (AMC).

Who are AxoGen's key executives?

AxoGen's management team includes the folowing people:
  • Ms. Karen Zaderej, Chairman, Pres & CEO (Age 57)
  • Mr. Peter J. Mariani, Chief Financial Officer (Age 55)
  • Mr. Gregory G. Freitag Esq., J.D., CPA, Gen. Counsel & Director (Age 57)
  • Mr. Michael Donovan, VP of Operations (Age 54)
  • Ms. Kaila Paige Krum, VP of Investor Relations & Corp. Devel.

Who are AxoGen's major shareholders?

AxoGen's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Peregrine Capital Management LLC (1.21%), Perkins Capital Management Inc. (0.90%) and Valeo Financial Advisors LLC (0.01%). Company insiders that own AxoGen stock include Amy Mcbride Wendell, Gregory Gene Freitag, Guido J Neels, Jamie Mark Grooms, Karen L Zaderej, Robert James Rudelius and Shawn F Mccarrey. View Institutional Ownership Trends for AxoGen.

Which institutional investors are selling AxoGen stock?

AXGN stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc. and Valeo Financial Advisors LLC. Company insiders that have sold AxoGen company stock in the last year include Gregory Gene Freitag, Karen L Zaderej and Shawn F Mccarrey. View Insider Buying and Selling for AxoGen.

Which institutional investors are buying AxoGen stock?

AXGN stock was bought by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC. View Insider Buying and Selling for AxoGen.

How do I buy shares of AxoGen?

Shares of AXGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AxoGen's stock price today?

One share of AXGN stock can currently be purchased for approximately $20.65.

How big of a company is AxoGen?

AxoGen has a market capitalization of $804.21 million and generates $83.94 million in revenue each year. The medical equipment provider earns $-22,400,000.00 in net income (profit) each year or ($0.54) on an earnings per share basis.

What is AxoGen's official website?

The official website for AxoGen is http://www.axogeninc.com.

How can I contact AxoGen?

AxoGen's mailing address is 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL, 32615. The medical equipment provider can be reached via phone at 386-462-6800 or via email at [email protected]


MarketBeat Community Rating for AxoGen (NASDAQ AXGN)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  337 (Vote Outperform)
Underperform Votes:  220 (Vote Underperform)
Total Votes:  557
MarketBeat's community ratings are surveys of what our community members think about AxoGen and other stocks. Vote "Outperform" if you believe AXGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AXGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/23/2019 by MarketBeat.com Staff

Featured Article: What is the Bid-Ask Spread?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel